Skip to main content

Table 3 Secondary outcome variables at 32 and 36 weeks postmenstrual age

From: Efficacy and safety of early supplementation with 800 IU of vitamin D in very preterm infants followed by underlying levels of vitamin D at birth

Variable Cord 25(OH)D concentrations <10 ng/mL (N = 20) Cord 25(OH)D concentrations ≥10 ng/mL (N = 29) P
At birth
 Serum calcium, mg/dL 7.0 ± 0.7 7.3 ± 0.8 0.12
 Serum phosphorus, mg/dL 5.0 ± 1.4 4.8 ± 1.4 0.51
 Serum ALP, IU/L 205.6 ± 63.7 178.8 ± 49.1 0.10
32 ± 1 weeks PMA
 Serum calcium, mg/dL 9.7 ± 0.5 9.4 ± 0.7 0.86
 Serum phosphorus, mg/dL 5.9 ± 0.9 5.2 ± 0.8 0.13
 Serum ALP, IU/L 366.5 ± 102.3 422.0 ± 138.5 0.05
 Serum PTH, pg/mL * 76.3 ± 50.1 74.2 ± 69.1 0.92
 Vitamin D excess (>80 ng/mL) 0 0 -
36 ± 1 weeks PMA
 Serum calcium, mg/dL 9.7 ± 0.4 9.7 ± 0.6 0.51
 Serum phosphorus, mg/dL 6.2 ± 0.6 5.7 ± 1.9 0.07
 Serum ALP, IU/L 284.6 ± 91.6 338.8 ± 127.1 0.11
 Vitamin D excess (>80 ng/mL) 0/17 3/26 0.27
 UCa/Cr 0.13 ± 0.16 0.19 ± 0.28 0.50
 UCa/Cr >0.8 0 1 (3%) 1.00
 Nephrocalcinosis, n 1 (5%) 2 (7%) 1.00
 Weight, g 1881.1 ± 254.1 1813.2 ± 331.3 0.44
 Length, cm 41.3 ± 1.5 40.5 ± 2.2 0.19
 Head circumference, cm 30.6 ± 1.2 29.6 ± 1.4 0.43
 BMC, g 2.6 ± 2.0 2.1 ± 1.7 0.44
 BMD, g/cm 0.11 ± 0.02 0.10 ± 0.02 0.63
  1. Data are presented as n (%), median (range), or mean ± SD unless otherwise indicated. -, could not be estimated because the data is skewed or categorical, or there are no events in both the groups
  2. ALP alkaline phosphatase, PMA postmenstrual age, PTH parathyroid hormone, BMC bone mineral content, BMD bone mineral density
  3. * n = 18 and 20 in the cord 25(OH)D concentration < 10 ng/mL and ≥ 10 ng/mL groups, respectively
  4. n = 12 and 19 in the cord 25(OH)D concentration < 10 ng/mL and ≥ 10 ng/mL groups, respectively